⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AYTU News
AYTU BioPharma, Inc. Common Stock
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
accessnewswire.com
AYTU
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
accessnewswire.com
AYTU
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
accessnewswire.com
AYTU
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
accessnewswire.com
AYTU
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
accessnewswire.com
AYTU
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
accessnewswire.com
AYTU
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
accessnewswire.com
AYTU
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
accessnewswire.com
AYTU
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
accessnewswire.com
AYTU
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
accessnewswire.com
AYTU